Immune checkpoint inhibitors (ICIs) have heralded the advent of a new era in oncology by holding the promise of prolonged survival in severe and otherwise treatment-refractory advanced cancers. However, the remarkable antitumor efficacy of these agents is overshadowed by their potential for inducing autoimmune toxic effects, collectively termed immune-related adverse events (irAEs). These autoimmune adverse effects are often difficult to predict, possibly permanent, and occasionally fatal. Hence, the identification of risk factors for irAEs is urgently needed to allow for prompt therapeutic intervention. This review discusses the potential mechanisms through which irAEs arise and summarizes the existing evidence regarding risk factors associated with the occurrence of irAEs. In particular, we examined available data regarding the effect of a series of clinicopathological and demographic factors on the risk of irAEs.
CITATION STYLE
Liu, X., Shi, Y., Zhang, D., Zhou, Q., Liu, J., Chen, M., … Wang, M. (2021, December 1). Risk factors for immune-related adverse events: what have we learned and what lies ahead? Biomarker Research. BioMed Central Ltd. https://doi.org/10.1186/s40364-021-00314-8
Mendeley helps you to discover research relevant for your work.